Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.

The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.

SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The fireside chat will take place on Thursday, November 20, 2025, at 5:30 a.m. Pacific Standard Time / 8:30 a.m. Eastern Standard Time. 

Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Thursday, November 20, 2025
Time: 5:30 a.m. PST / 8:30 a.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Brian Price
Press@ceribell.com

FAQ

When will Ceribell CFO Scott Blumberg speak at the Canaccord Genuity forum (CBLL)?

The fireside chat is on November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST.

How can investors watch Ceribell (CBLL) at the Canaccord Genuity MedTech forum?

A live and archived webcast will be available on Ceribell's Investor Relations website at https://investors.ceribell.com/.

What topics will Ceribell (CBLL) cover at the Canaccord Genuity MedTech forum?

The announcement states CFO Scott Blumberg will take part in a fireside chat; specific topics were not disclosed.

Who is representing Ceribell (CBLL) at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum?

Ceribell will be represented by CFO Scott Blumberg in a fireside chat.

Where is the Canaccord Genuity MedTech forum where Ceribell (CBLL) will appear?

The forum is in New York; the company will also provide a webcast via its investor site.

Will the Ceribell (CBLL) fireside chat be available after November 20, 2025?

Yes. An archived webcast will be available on the company's Investor Relations page following the event.